<?xml version="1.0" encoding="UTF-8"?>
<p>While an active vaccine against GAS is an ideal outcome, many successful vaccines do not abolish disease including the pneumococcal, Hib, and influenza vaccines [
 <xref rid="pone.0235139.ref071" ref-type="bibr">71</xref>â€“
 <xref rid="pone.0235139.ref074" ref-type="bibr">74</xref>]. Therefore, the development of therapeutic antibodies designed as an adjunct treatment for severe iGAS diseases, including IAV-GAS superinfections, may prove to be beneficial, particularly during influenza pandemics.
</p>
